Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.

Qin C, Cao Q, Li P, Wang S, Wang J, Wang M, Chu H, Zhou L, Li X, Ye D, Zhang H, Huang Y, Dong B, Sun X, Zou Q, Cai H, Sun L, Zhu J, Liu F, Ji J, Cui L, Wang X, Zhou H, Zhao H, Wu B, Chen J, Jiang M, Zhang Z, Shao P, Ju X, Yin C.

Sci Rep. 2016 Feb 2;6:20089. doi: 10.1038/srep20089.

2.

Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.

Kim A, Widemann BC, Krailo M, Jayaprakash N, Fox E, Weigel B, Blaney SM.

Pediatr Blood Cancer. 2015 Sep;62(9):1562-6. doi: 10.1002/pbc.25548. Epub 2015 Apr 27.

3.

Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E.

Ann Oncol. 2015 Oct;26(10):2017-26. doi: 10.1093/annonc/mdv244. Epub 2015 Jun 1. Review.

4.

Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.

Sharan S, Woo S.

Front Pharmacol. 2015 Feb 20;6:33. doi: 10.3389/fphar.2015.00033. eCollection 2015.

5.

The discovery and development of sorafenib for the treatment of thyroid cancer.

White PT, Cohen MS.

Expert Opin Drug Discov. 2015 Apr;10(4):427-39. doi: 10.1517/17460441.2015.1006194. Epub 2015 Feb 8. Review.

6.

Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.

Massey PR, Okman JS, Wilkerson J, Cowen EW.

Support Care Cancer. 2015 Jun;23(6):1827-35. doi: 10.1007/s00520-014-2520-9. Epub 2014 Dec 5. Review.

7.

Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.

Meadows KL, Rushing C, Honeycutt W, Latta K, Howard L, Arrowood CA, Niedzwiecki D, Hurwitz HI.

Support Care Cancer. 2015 May;23(5):1311-9. doi: 10.1007/s00520-014-2465-z. Epub 2014 Oct 24.

8.

Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.

Chuang HY, Chang YF, Liu RS, Hwang JJ.

PLoS One. 2014 Oct 15;9(10):e109992. doi: 10.1371/journal.pone.0109992. eCollection 2014.

9.

Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.

Loibl S, Rokitta D, Conrad B, Harbeck N, W├╝llner M, Warm M, Schwedler K, Gerber B, Schrader I, Eidtmann H, Mehta K, Fuhr U, von Minckwitz G.

Breast Care (Basel). 2014 Jul;9(3):169-74. doi: 10.1159/000363430.

10.

Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma.

Sil A, Das NK.

Indian J Pharmacol. 2014 May-Jun;46(3):334-6. doi: 10.4103/0253-7613.132189.

11.

Sorafenib Induced Hand Foot Skin Rash in FLT3 ITD Mutated Acute Myeloid Leukemia-A Case Report and Review of Literature.

Senapati J, Devasia AJ, Ganapule A, George L, Viswabandya A.

Mediterr J Hematol Infect Dis. 2014 Feb 17;6(1):e2014016. doi: 10.4084/MJHID.2014.016. eCollection 2014.

12.

Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.

Chen M, Zhang L, Wang Q, Shen J.

PLoS One. 2013 Aug 20;8(8):e72245. doi: 10.1371/journal.pone.0072245. eCollection 2013. Review.

13.

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.

Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, Durand JP, Coriat R, Dauphin A, Vidal M, Tod M, Loriot MA, Goldwasser F, Blanchet B.

PLoS One. 2012;7(8):e42875. doi: 10.1371/journal.pone.0042875. Epub 2012 Aug 13.

14.

Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.

Boudou-Rouquette P, Ropert S, Mir O, Coriat R, Billemont B, Tod M, Cabanes L, Franck N, Blanchet B, Goldwasser F.

Oncologist. 2012;17(9):1204-12. Epub 2012 Jul 2.

15.

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.

Dranitsaris G, Vincent MD, Yu J, Huang L, Fang F, Lacouture ME.

Ann Oncol. 2012 Aug;23(8):2103-8. doi: 10.1093/annonc/mdr580. Epub 2012 Jan 6.

16.

Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.

Gomez P, Lacouture ME.

Oncologist. 2011;16(11):1508-19. doi: 10.1634/theoncologist.2011-0115. Epub 2011 Oct 20. Review.

17.

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.

Desar IM, Timmer-Bonte JN, Burger DM, van der Graaf WT, van Herpen CM.

Br J Cancer. 2010 Nov 23;103(11):1637-43. doi: 10.1038/sj.bjc.6605777. Epub 2010 Nov 2.

18.

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.

Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD.

J Exp Clin Cancer Res. 2010 Jul 14;29:95. doi: 10.1186/1756-9966-29-95.

19.

Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.

Stone RL, Sood AK, Coleman RL.

Lancet Oncol. 2010 May;11(5):465-75. doi: 10.1016/S1470-2045(09)70362-6. Epub 2010 Mar 10. Review.

20.

Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.

Jain L, Gardner ER, Figg WD, Chernick MS, Kong HH.

Pharmacotherapy. 2010 Jan;30(1):52-6. doi: 10.1592/phco.30.1.52.

Supplemental Content

Support Center